A CAR T-cell therapy treatment for advanced non-small-cell lung cancer (NSCLC) is effective in treating primary relapsed or relapsed NSCLC in a subset of patients, according to an abstract of the study by lead author Andrés Lachmannian and colleagues at the Alcala National Food and Drug Research Institute (CNIO), the Madrid-based nonprofit organization whose grant…